OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions. Its pharmaceutical segment consists of two operating segments: pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, diagnostic tests and vaccines, and the pharmaceutical operations, which it acquired in Chile, Mexico and Israel. In August 2013, OPKO Health Inc announced the completion of the acquisition of PROLOR.